Biocodex

Address: 22 Rue Des Aqueducs

Sponsor Overview

assignment

Specializations

Gastrointestinal Disorders

Research activity includes irritable bowel syndrome, with a focus on global symptom burden and patient-reported digestive outcomes, alongside interest in gut microbiota modulation during antibiotic therapy.

Non-constipated irritable bowel syndrome
Saccharomyces boulardii CNCM I-745
Microbiome support during antibiotic exposure

The sponsor’s work in this area centers on digestive symptom management and the interaction between antimicrobial treatment and intestinal microbial balance.

Rare Metabolic Disease

Clinical research covers primary hyperoxaluria across multiple subtypes, with attention to reducing urinary oxalate excretion and addressing the metabolic consequences of inherited oxalate overproduction.

Primary hyperoxaluria type 1
Primary hyperoxaluria type 2
Primary hyperoxaluria type 3

Interest in this field reflects involvement in disorders linked to kidney stone formation and systemic metabolic complications.

Neurology and Epilepsy

Biocodex supports studies in Dravet syndrome, a severe developmental and epileptic encephalopathy, with therapeutic interest in seizure control and neurological disease management.

Dravet syndrome
Epileptic encephalopathy
Pediatric neurological disorders

This area highlights engagement with complex childhood-onset neurological conditions requiring long-term clinical care.

Renal Impairment and Pharmacokinetics

Research also addresses renal impairment, with interest in how kidney dysfunction affects drug handling and treatment exposure in patients receiving oral therapies.

Renal function impairment
Pharmacokinetic evaluation
Oral medicinal product performance

These studies connect kidney disease with medication use in populations requiring careful therapeutic adaptation.

Trial Name	Country	Status
Bioavailability Assessment of Stiripentol Following Single Oral Administration of Two Formulations in Healthy Subjects: A Study in Dravet Syndrome Context	France	Not Recruiting
Efficacy and Safety Assessment of Stiripentol in Patients Aged 6 and Older with Primary Hyperoxaluria Types 1, 2, or 3	Belgium France Italy	Recruiting
Efficacy and Safety Evaluation of Saccharomyces boulardii CNCM I-745 in Non-Constipated Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial	Portugal Spain	Recruiting
Evaluation of Saccharomyces boulardii CNCM I-745 and Amoxicillin on Gut Microbiota in Patients with Erythema Migrans Undergoing Antibiotic Therapy	Czechia Lithuania Slovakia Slovenia	Recruiting
Pharmacokinetic Evaluation of Stiripentol in Patients with Renal Impairment Versus Healthy Controls: An Open-Label Phase I Study	Bulgaria	Not Recruiting